DexCom (DXCM) Earning Somewhat Favorable Media Coverage, Study Finds
Media stories about DexCom (NASDAQ:DXCM) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. DexCom earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave media headlines about the medical device company an impact score of 46.0428515441619 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Executive Chairman of Dexcom Inc (NASDAQ:DXCM), Gregg Terrance H, sells 10,000 shares worth $568,588 (empowerednews.net)
- DexCom, Inc. (DXCM) Insider Sells $568,600.00 in Stock (americanbankingnews.com)
- What’s Happening With These Medical Research Stocks? — Organovo, BioTelemetry, Bruker, and DexCom (forimmediaterelease.net)
- Zacks: Brokerages Expect DexCom, Inc. (DXCM) Will Announce Quarterly Sales of $217.73 Million (americanbankingnews.com)
- DexCom, Inc. (DXCM) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
DXCM has been the topic of a number of research analyst reports. TheStreet cut DexCom from a “c-” rating to a “d+” rating in a report on Wednesday, October 25th. Wedbush restated a “buy” rating and set a $76.00 price target on shares of DexCom in a report on Wednesday, October 4th. Raymond James Financial cut DexCom from an “outperform” rating to a “mkt perform” rating in a report on Friday, September 29th. Northland Securities assumed coverage on DexCom in a report on Tuesday, September 26th. They set an “outperform” rating and a $85.00 price target on the stock. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $69.00 target price (down from $90.00) on shares of DexCom in a research report on Thursday, September 28th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the company. DexCom currently has an average rating of “Buy” and an average price target of $68.50.
DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.11. DexCom had a negative return on equity of 20.44% and a negative net margin of 7.21%. research analysts predict that DexCom will post -0.65 EPS for the current fiscal year.
In related news, insider Terrance H. Gregg sold 10,000 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total value of $568,600.00. Following the completion of the sale, the insider now directly owns 484,559 shares of the company’s stock, valued at approximately $27,552,024.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Andrew K. Balo sold 3,245 shares of the stock in a transaction on Monday, December 11th. The shares were sold at an average price of $61.23, for a total value of $198,691.35. The disclosure for this sale can be found here. Insiders sold a total of 46,505 shares of company stock valued at $2,653,896 over the last three months. 1.70% of the stock is currently owned by insiders.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.